Beyond RAS and BRAF: a target rich disease that is ripe for picking

Area of Science:

• Oncology
• Genetics

Background:

• Colorectal cancer treatment, particularly for metastatic disease, relies heavily on empiric approaches despite advances in understanding oncogenic mutations.
• Current routine testing for rat sarcoma virus (RAS) and rapidly growing fibrosarcoma (RAF) mutations primarily serves as negative predictive markers for EGFR inhibitor response and prognostic indicators, rather than direct therapeutic targets.

Approach:

• This review explores emerging molecular targets identified through next-generation sequencing (NGS) in advanced colorectal cancer.
• Focuses on common and rare mutations offering potential for novel targeted therapies.

Key Points:

• Next-generation sequencing is identifying a growing number of actionable mutations in colorectal cancer.
• These mutations represent promising targets for developing more precise and personalized therapeutic strategies.
• The identification of novel targets is shifting the paradigm towards precision medicine in colorectal cancer care.

Conclusions:

• The landscape of metastatic colorectal cancer treatment is rapidly advancing towards personalized medicine.
• Future therapeutic strategies will increasingly leverage specific molecular targets identified through advanced genomic profiling.